ClinicalTrials.gg
Status unknownNCT04856397DMEUpdated May 12, 2021

Ozurdex in Suboptimal Diabetic Macular Edema Patients

An interventional study of Intravitreal Implant in Applicator and Eylea in Diabetic Macular Edema, sponsored by Uptown Eye Specialists. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Uptown Eye Specialists · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary focus of this study is to understand the anatomic and visual outcomes of patients with refractory and suboptimal treatment response diabetic macular edema (DME) using anti-vascular endothelial growth factor (VEGF) to Ozurdex, an intravitreal dexamethasone implant. Secondly, investigators aim to understand the differences in cytokine profiles in patients who respond differently to intravitreal anti-VEGF versus Ozurdex. The importance of this study is to identify biomarkers that may help predict patients' response to different treatment protocols. Currently, Ozurdex is not covered by provincial health benefit plans for patients with DME. Our results may help improve access to care for those who have suboptimal results with or refractory to intravitreal anti-VEGF treatment.

Read the detailed description

Diabetic macular edema (DME) is the most common cause of vision loss in young patients with diabetes. Its pathophysiology starts with decreased retinal oxygen tension that manifests as retinal capillary hyperpermeability and increased intravascular pressure mediated by vascular endothelial growth factor (VEGF) upregulation and retinal vascular autoregulation, respectively. Spectral domain optical coherence tomography (SD-OCT) is the cornerstone of clinical assessment of DME. The foundation of treatment is metabolic control of hyperglycemia and blood pressure. Specific ophthalmic treatments of DME include intravitreal anti-VEGF drug injections, in the form of intravitreal Bevacizumab (Avastin), Ranibizumab (Lucentis), and Aflibercept (Eylea). Intravitreal corticosteroid injections, focal laser photocoagulation, and vitrectomy are other treatment options. A substantial fraction of eyes respond incompletely to all of these modalities resulting in visual loss and disordered retinal structure and vasculature visible on SD-OCT and OCT angiography. There is currently no consensus on when to switch from one treatment to another in the context of a suboptimal response. Our hypothesis is that patients who are switched early to Ozurdex and achieve an OCT proven dry state, achieve better functional outcomes than those patients who are switched late or not at all, by limiting exposure of the retina to potentially damaging inflammatory markers, and the merits associated with less frequent injections.

Suboptimal DME is defined as a central subfoveal retinal thickness of > 300 and the presence of intra or sub-retinal fluid with a minimum BCVA of 20/25 or worse after 3 injections of intravitreal aflibercept, from here on referred to as Eylea. Furthermore, there is some evidence that a subset of patients with refractory DME respond well to intravitreal corticosteroids, specifically, Ozurdex, which is a biodegradable, sustained-release intravitreal dexamethasone implant, designed to be potentially injected between 2-6 months. This medication is currently not covered by the Ontario health benefits plan for patients with DME and comes at a significant cost to patients.

Moreover, recent studies have confirmed the important role of inflammatory ocular cytokines in patients' response to intravitreal treatments in DME, much the same as neovascular age-related macular degeneration. However, it is not known which ocular cytokines determine the degree of response to various treatment modalities for DME.

Here, investigators aim to study the anatomic and visual outcomes, as well as the cytokine profile of patients with suboptimal DME in response to early vs. late switch to intravitreal Ozurdex treatment.

02

Conditions studied

  • Diabetic Macular Edema

Browse trials for

03

In context

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

This study's planned enrollment of 200 is above the median of 56 across 587 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Uptown Eye Specialists is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Treatment-native patients with DME secondary to type I or type II diabetes mellitus
  2. Patients who require intravitreal anti-VEGF treatment
  3. Able to understand English and complete a pain assessment
  4. Suboptimal DME responders in patients who have received 3 or 6 eylea injections (non-cytokine group)

Exclusion criteria

Exclusion Criteria:

  1. Deafness or communication disorder, known Dementia, Severe /Asthma (severe lung disorder), Severe OSA, Psychiatric or Anxiety conditions, involuntary movement disorders, allergy to the anesthesia, any conditions requiring intraoperative iris manipulation, any prior ocular surgery; all patients who may need translation, are illiterate, or unable to provide consent.
  2. Pre-existing ocular pathology confounding outcome (i.e. uveitis, retinal vascular disease, macular degeneration etc.)
  3. Pre-existing uncontrolled glaucoma/high IOP
  4. Patients under 18
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Control group

    Responders will be in this category. These patients will be maintained on intravitreal anti-VEGF therapy for 1 year, with a monthly PRN ("as needed") treatment regimen post 5 monthly loading doses.

    Drug: Eylea

  • Experimental
    Early switch

    Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 3 monthly loading intravitreal eylea.

    Drug: Intravitreal Implant in Applicator · Drug: Eylea

  • Experimental
    Late switch

    Suboptimal responders who are switched to intravitreal Ozurdex (monitored monthly and treated PRN at a potential 2-6 month interval) injections after the first 6 monthly loading intravitreal eylea

    Drug: Intravitreal Implant in Applicator · Drug: Eylea

  • Other
    Non-switch

    Suboptimal responders who continue to receive monthly intravitreal anti-VEGF injections.

    Drug: Eylea

Interventions

  • DrugIntravitreal Implant in Applicator

    Dexamethasone intravitreal implant

    Also known as: Ozurdex

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    anti-VEGF medication

06

What researchers measure

Primary outcomes

  1. Visual acuity

    best corrected visual acuity (BCVA)

    Time frame: 1 year

Secondary outcomes

  1. OCT findings

    Track anatomic outcomes on optical coherence tomography (OCT)

    Time frame: 1 year

  2. OCTa findings

    Track anatomic outcomes on optical coherence tomography angiography (OCTA)

    Time frame: 1 year

  3. Cytokine expression TNFa

    baseline cytokine profile of the aqueous humour of all patients prior to first dose of anti-VEGF. Cytokine TNFa

    Time frame: 1 year

  4. Cytokine expression IL-8

    baseline cytokine profile of the aqueous humour of all patients prior to first dose of anti-VEGF. Cytokine IL-8

    Time frame: 1 year

  5. Cytokine expression IL-6

    baseline cytokine profile of the aqueous humour of all patients prior to first dose of anti-VEGF. Cytokine IL-6

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2021; primary completion for Aug 2021, 3 months later.

Of 47 non-industry interventional studies with no phase under Macular Edema, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 3 months is below that.

Counting every sponsor, half of 51 studies reached it within 18 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Apr 23, 2021
StartEst.
May 25, 2021
Primary completionEst.
Aug 30, 2021
CompletionEst.
Dec 29, 2021
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04856397
Lead sponsor
Uptown Eye Specialists
Responsible party
Sohel Somani (Principal Investigator, Uptown Eye Specialists) — Principal investigator
First posted
Apr 23, 2021
Start date
May 25, 2021 (estimated)
Primary completion
Aug 30, 2021 (estimated)
Completion
Dec 29, 2021 (estimated)
Last update
May 12, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion